Stryker CORP

Stryker Corporation announced robust second quarter 2026 financial results, with net sales up 9.4% and EPS soaring 44.1%, signaling a strong recovery post-cyber incident.

Stryker Corporation has recast its historical financial statements to reflect a new organizational structure, creating an 'Ortho Tech' business segment.

Stryker Corporation announces the retirement of its Vice President and Chief Accounting Officer, William E. Berry, Jr., effective September 1, 2026, with Emily Baculik appointed as his successor.

Stryker Corporation shareholders re-elected all ten directors, ratified the appointment of Ernst & Young LLP, and approved executive compensation at the 2026 Annual Meeting.

Stryker reported a 2.6% increase in Q1 2026 net sales to $6.0 billion, maintaining full-year guidance despite a recent cybersecurity incident.

Stryker Corporation filed an amendment to its Form 8-K, providing further details on a material cybersecurity incident that impacted its operations in Q1 2026.

Stryker Corporation announced a 9.4% increase in net sales for the second quarter of 2026, reaching $6,589 million, driven by robust performance across its MedSurg and Orthopaedics segments.

Stryker Corporation announced its first quarter 2026 financial results, with net sales increasing by 2.6% to $6.02 billion, driven by higher unit volumes across key segments.

Stryker Corporation reported a 10.3% increase in net sales for the third quarter of 2025, driven by strong unit volume and the strategic acquisition of Inari Medical.

Stryker Corporation announced robust sales growth for the second quarter and first half of 2025, driven by strong organic performance and strategic acquisitions, despite a decline in GAAP net earnings for the six-month period due to integration costs and impairments.

Stryker Corporation's Q1 2025 results show an 11.9% increase in sales, driven by the acquisition of Inari Medical and strong organic growth, though net earnings per diluted share decreased.

Stryker Corporation's third-quarter results show a significant increase in sales and earnings, driven by higher unit volume across its MedSurg and Neurotechnology and Orthopaedics and Spine segments.

Stryker Corporation achieved robust net sales and adjusted earnings growth in 2025, driven by strategic acquisitions and innovative product launches across its MedSurg, Neurotechnology, and Orthopaedics segments.

Stryker Corporation's 2024 Form 10-K reveals a year of solid growth, strategic acquisitions, and a significant portfolio reorganization, alongside detailed financial performance and risk assessments.

Stryker Corporation's 10-K filing details the structure of its capital stock, including common and preferred shares, and describes various debt securities issued by the company.

Ronda E Stryker, a Director of Stryker Corp, sold 350,000 shares of common stock on August 18, 2026.

Debra King, See Remarks of Stryker Corp, sold 826 shares of common stock on August 18, 2026 for $336.30 per share.

Kimberly Ann Montagnino, VP, Chief Comm. Officer of Stryker Corp, reported a transaction in 155 shares of common stock on August 1, 2026.

Debra King, See Remarks of Stryker Corp, reported a transaction in 533 shares of common stock on August 1, 2026.

Robert S Fletcher, VP, Chief Legal Officer of Stryker Corp, reported a transaction in 94 shares of common stock on August 1, 2026.

M Kathryn Fink, VP, Chief HR Officer of Stryker Corp, reported a transaction in 111 shares of common stock on August 1, 2026.

Stryker Corporation's latest proxy statement reveals robust 2025 financial performance, strong executive compensation alignment, and key corporate governance updates ahead of its 2026 Annual Meeting.

Stryker Corporation has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Stryker Corporation's upcoming annual shareholder meeting on May 8, 2025, will address key items including director elections, ratification of the accounting firm, and approval of incentive plans.

Stryker Corporation has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Stryker Corporation's definitive proxy statement outlines details for the 2024 annual shareholder meeting, including voting matters, director nominees, executive compensation, and corporate governance practices.

Ronda E. Stryker has updated her Schedule 13D filing to report a change of at least 1% in her beneficial ownership of Stryker Corp common stock.

Vanguard Capital Management has reported beneficial ownership of 25,802,180 shares, representing 6.73% of Stryker Corp's common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G for Stryker Corp, reporting 0% beneficial ownership following an internal realignment.

Greenleaf Trust has filed an amendment to its Schedule 13G, reporting a decrease in its beneficial ownership of Stryker Corporation's common stock to 4.4%.

Greenleaf Trust has filed an Amendment No. 18 to its Schedule 13G, disclosing a 4.7% beneficial ownership stake in Stryker Corp as of December 31, 2024.